| Code | CSB-RA011614MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Gevokizumab, targeting interleukin-1 beta (IL1B), a potent pro-inflammatory cytokine central to innate immune responses. IL1B plays a critical role in mediating inflammatory cascades, fever induction, and acute phase responses. Dysregulated IL1B signaling is implicated in numerous pathological conditions, including autoinflammatory diseases, type 2 diabetes, cardiovascular disease, and various inflammatory disorders. Excessive IL1B production contributes to chronic inflammation and tissue damage in conditions such as rheumatoid arthritis, inflammatory bowel disease, and certain ocular inflammatory conditions.
Gevokizumab is a humanized IgG2 monoclonal antibody that uniquely modulates IL1B activity through allosteric inhibition rather than complete blockade, selectively reducing its interaction with the IL-1 receptor while maintaining some physiological signaling. This antibody serves as a valuable research tool for investigating IL1B-mediated inflammatory pathways, studying cytokine signaling mechanisms, and exploring therapeutic interventions in inflammation-related research models. It enables researchers to examine the nuanced role of IL1B in disease pathogenesis and immune regulation.
There are currently no reviews for this product.